Overview
- Insulet, which reported results Wednesday, posted revenue of $761.7 million and GAAP profit of $91.1 million for the first quarter.
- Adjusted earnings were $1.42 per share, beating Wall Street forecasts as sales topped the roughly $730 million consensus.
- The company lifted its 2026 total revenue growth outlook to 21%–23% after the stronger-than-expected start to the year.
- Omnipod, Insulet’s wearable insulin pump, generated $758.4 million in sales, up 36.9% from a year earlier.
- Insulet repurchased 1.25 million shares and highlighted new Middle East rollouts and progress toward fully closed-loop insulin delivery.